Igenica

Biotech · Private

Monoclonal antibodies and antibody-drug conjugates (ADCs) targeting novel cancer antigens

igenica.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1694NEMUCORE MEDICAL INNOVATIONS, INC.——
1695Epigen Biosciences, Inc.——
1696ONECYTE BIOTECHNOLOGIES, INC.——
1697Igenica——
1698ZabBio, Inc.——
1699EVOQ THERAPEUTICS, INC.——
1700OMass Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Novel Linkers For Antibody-drug Conjugates And Related Compounds, Compositions, And Methods Of Useapplication
  • Novel Linkers For Antibody-drug Conjugates And Related Compounds, Compositions, And Methods Of Useapplication
  • Antibody-Drug Conjugates, Compositions and Methods of Useapplication
  • ANTI-CD98 Antibodies And Methods Of Use Thereofapplication
  • ANTI-CD98 Antibodies And Methods Of Use Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.